Abstract
Introduction
Cystic prolactinoma is a variant of prolactin-secreting pituitary adenoma. The strategies for the management of cystic prolactinoma have not been addressed thoroughly in clinical guidelines.
Methods
A literature search was performed using Pubmed to review the current approaches to the treatment of cystic prolactinoma.
Results
Transsphenoidal resection is an effective and relatively safe approach for the treatment of cystic prolactinoma, however, morbidity of surgery is dependent on the skill of the surgeon. Emerging studies allude to the efficacy and safety of dopamine agonists in the management of cystic prolactinoma. Dopamine agonists are associated with considerable rates of clinical improvement and tumor shrinkage, hence reducing the need for surgical intervention.
Conclusions
Recent studies suggest that dopamine agonist therapy may be an effective and safe treatment option in a considerable portion of patients with cystic prolactinomas. We suggest that dopamine agonists should be considered as a first-line therapy for cystic prolactinoma in the absence of indications for early surgical intervention.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Iglesias P, Díez JJ (2013) Macroprolactinoma: a diagnostic and therapeutic update. QJM 106:495–504
Karavitaki N, Thanabalasingham G, Shore HC et al (2006) Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified nonfunctioning pituitary macroadenoma. Clin Endocrinol 65:524–529
Faje A, Chunharojrith P, Nency J et al (2016) Dopamine agonists can reduce cystic prolactinomas. J Clin Endocrinol Metab 101:3709–3715
Casanueva FF, Molitch ME, Schlechte JA et al (2006) Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol 65:265–273
Melmed S, Casanueva FF, Hoffman AR et al (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:273–288
Ogiwara T, Horiuchi T, Nagm et al (2017) Significance of surgical management for cystic prolactinoma. Pituitary 20(2):225–230
Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158:11–18
Bahuleyan B, Menon G, Nair S, Rao BR, Easwer HV, Krishna K (2009) Non-surgical management of cystic prolactinomas. J Clin Neurosci 16:1421–1424
Bukowczan J, Lois K, Mathiopoulou M, Grossman AB, James RA (2016) Reversal of severe cognitive impairment following medical treatment of cystic invasive giant prolactinoma. Endocrinol Diabet Metab Case Rep 2016:150111. https://doi.org/10.1530/EDM-15-0111
Delgrange E, Gustin T (2005) Cystic macroprolactinoma: primary medical treatment? Intern Med J 35:687–688
Prague JK, Ward CL, Mustafa OG, Whitelaw BC, King A, Thomas NW, Gilbert J (2014) Delayed presentation of late-onset cerebrospinal fluid rhinorrhea following dopamine agonist therapy for giant prolactinoma. Endocrinol Diabet Metab Case Rep 2014:140020. https://doi.org/10.1530/EDM-14-0020
Lima GAB, Machado Ede O, Dos Santos Silva CM, Filho PN, Gadelha MR (2008) Pituitary apoplexy during treatment of cystic macroprolactinomas with cabergoline. Pituitary 11:287–292
Briet C, Salenave S, Bonneville JF, Laws ER, Chanson P (2015) Pituitary apoplexy. Endocr Rev 36(6):622–645
Nishioka H, Haraoka J, Akada K, Azuma S (2002) Gender-related differences in prolactin secretion in pituitary prolactinomas. Neuroradiology 44(5):407–410
Inder WJ, Macfarlane MR (2004) Hyperprolactinaemia associated with a complex cystic pituitary mass: medical versus surgical therapy. Intern Med J 34:573–576
Park M, Lee SK, Choi J et al (2015) Differentiation between cystic pituitary adenomas and Rathke cleft cysts: a diagnostic model using MRI. AJNR Am J Neuroradiol 36:1866–1873
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that there are no conflicts of interest.
Rights and permissions
About this article
Cite this article
Nakhleh, A., Shehadeh, N., Hochberg, I. et al. Management of cystic prolactinomas: a review. Pituitary 21, 425–430 (2018). https://doi.org/10.1007/s11102-018-0888-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11102-018-0888-0